News

Bausch & Lomb will evaluate the compound's potential as a novel anti-inflammatory medication with an improved safety profile for ophthalmic indications. Glucocorticoids are the most potent and frequently

The treatment, which will be particularly focused on lung cancer patients, is known as Xyotax and is a biologically-enhanced chemotherapeutic. The investigational medicine is currently in phase III

The drug was manufactured to prevent the development of type 2 diabetes in non-diabetic patients. Patients taking ramipril showed no difference to the placebo group after three years.

New Jersey-based Schering-Plough is contemplating making an offer for the company, which recently dismissed its CEO, according to the Star-Ledger. The report cited three people with knowledge of

These drugs, called histone deacetylase inhibitors, are still under development. The report examined the potential use of the drugs in promoting regeneration and repair of dystrophic muscles, thereby

Fosrenol is designed to remove high blood phosphorous levels after dialysis in patients with chronic kidney problems. In March 2004, AnorMed sold the global patent rights for Fosrenol

Phase I/II trials indicated that after 12 months, patients exhibited a relapse rate reduction of more than 90%. The company has initiated its phase IIb study with Tovaxin

Orphan medicinal products are for diagnosing, preventing or treating life-threatening or very serious conditions that are rare and affect less than five of every 10,000 persons in the

A study of Diamyd demonstrated safety and efficacy in slowing the decline of C-peptide levels at 15 months. Diamyd patients also required less insulin than placebo and patients